260
Participants
Start Date
January 20, 2021
Primary Completion Date
July 30, 2021
Study Completion Date
July 7, 2022
GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1
Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
Normal saline (0.9% sodium chloride solution) - Stage 1
Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1
Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
Normal saline (0.9% sodium chloride solution) - Stage 1
Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 2
Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
GBP510 adjuvanted with Alum (RBD 25μg/dose)- Stage 2
Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
Normal saline (0.9% sodium chloride solution)- Stage 2
Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
Korea University Ansan Hospital, Ansan
Dong-A University Hospital, Busan
Kyungpook National University Chilgok Hospital, Daegu
Kyungpook National University Hospital, Daegu
Chonnam National University Hospital, Gwangju
Gachon University Gil Medical Center, Incheon
Inha University Hospital, Incheon
Ewha Womans University Medical Center, Seoul
Hallym University Medical Center, Seoul
Korea University Anam Hospital, Seoul
Korea University Guro Hospital, Seoul
Ajou University Hospital, Suwon
Coalition for Epidemic Preparedness Innovations
OTHER
SK Bioscience Co., Ltd.
INDUSTRY